Firethorn Wealth Partners LLC Acquires New Shares in Danaher Corporation $DHR

Firethorn Wealth Partners LLC bought a new position in shares of Danaher Corporation (NYSE:DHR) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 13,227 shares of the conglomerate’s stock, valued at approximately $2,930,000. Danaher accounts for about 0.9% of Firethorn Wealth Partners LLC’s investment portfolio, making the stock its 26th biggest position.

Other large investors also recently modified their holdings of the company. EP Wealth Advisors LLC acquired a new position in shares of Danaher during the second quarter valued at about $3,807,000. Puzo Michael J bought a new stake in shares of Danaher during the second quarter worth about $8,624,000. Madison Asset Management LLC acquired a new stake in shares of Danaher in the 2nd quarter worth about $85,451,000. First Nebraska Trust Co acquired a new stake in shares of Danaher in the 2nd quarter worth about $14,106,000. Finally, Colton Groome Financial Advisors LLC acquired a new stake in shares of Danaher in the 3rd quarter worth about $592,000. 79.05% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

DHR has been the topic of several recent research reports. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $240.00 price target on shares of Danaher in a research report on Wednesday, July 22nd. Guggenheim boosted their price objective on Danaher from $200.00 to $250.00 and gave the stock a “buy” rating in a report on Thursday, October 1st. TD Cowen increased their price objective on Danaher from $236.00 to $255.00 and gave the stock a “buy” rating in a research note on Tuesday. Royal Bank Of Canada raised their target price on Danaher from $215.00 to $250.00 and gave the company an “outperform” rating in a report on Monday, October 5th. Finally, Stifel Nicolaus dropped their target price on Danaher from $260.00 to $220.00 and set a “buy” rating on the stock in a report on Wednesday, July 22nd. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $235.41.

Danaher News Summary

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher and NVIDIA announced a collaboration combining Danaher’s scientific instruments, laboratory workflows, automation technologies and data with NVIDIA’s accelerated computing and AI capabilities. The companies aim to advance autonomous science and speed up research, potentially creating new growth opportunities in life-science tools. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Danaher is reportedly preparing to launch its first AI-powered autonomous laboratory, expected to operate at commercial scale in early 2027. The initiative could support demand for Danaher’s instruments, software and laboratory automation offerings as AI adoption expands. How to Invest in AI Drug Discovery
• Positive Sentiment: Zacks said Danaher has two indicators associated with a potential earnings beat ahead of its upcoming report. A stronger-than-expected result could reinforce investor confidence following the company’s previous quarterly beat on revenue and earnings. Danaher Earnings Expected to Grow
• Positive Sentiment: Morgan Stanley maintained its $240 price target for DHR, signaling continued confidence in the stock’s outlook and leaving room for further appreciation based on the referenced trading level. Morgan Stanley Keeps $240 Target for Danaher
• Neutral Sentiment: Danaher appointed Daniel L. Comas and Robert Hershberg to its board, expanding it to 13 members. The appointments may strengthen governance and industry expertise but are unlikely to materially affect near-term trading. Danaher Announces Board Appointments

Danaher Stock Up 0.6%

NYSE:DHR traded up $1.26 on Wednesday, hitting $224.10. The stock had a trading volume of 1,890,805 shares, compared to its average volume of 4,448,106. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65. The stock has a market cap of $157.54 billion, a P/E ratio of 39.79, a price-to-earnings-growth ratio of 2.78 and a beta of 0.76. Danaher Corporation has a 1 year low of $160.93 and a 1 year high of $242.80. The firm’s fifty day simple moving average is $212.41 and its two-hundred day simple moving average is $195.13.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.85 by $0.09. The company had revenue of $6.26 billion during the quarter, compared to analyst estimates of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. Danaher’s quarterly revenue was up 5.5% compared to the same quarter last year. During the same quarter last year, the business posted $0.77 EPS. Analysts predict that Danaher Corporation will post 8.53 earnings per share for the current year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend is Wednesday, September 30th. Danaher’s dividend payout ratio is 28.42%.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.